Nandrolone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Nandrolone
Accession Number
DB13169
Type
Small Molecule
Groups
Experimental, Investigational
Description

Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a synthetic anabolic-androgenic steroid (AAS) derived from testosterone.

Structure
Thumb
Synonyms
  • (17β)-17-hydroxyestr-4-en-3-one
  • 19-norandrostenolone
  • 19-nortestosterone
  • Nandrolona
  • Nandrolone
  • Nandrolonum
External IDs
NSC-3351
International/Other Brands
Menidrabol
Categories
UNII
6PG9VR430D
CAS number
434-22-0
Weight
Average: 274.3978
Monoisotopic: 274.193280076
Chemical Formula
C18H26O2
InChI Key
NPAGDVCDWIYMMC-IZPLOLCNSA-N
InChI
InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1
IUPAC Name
(1S,2R,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinNandrolone may increase the anticoagulant activities of (R)-warfarin.
(S)-WarfarinNandrolone may increase the anticoagulant activities of (S)-Warfarin.
2,4-thiazolidinedioneNandrolone may increase the hypoglycemic activities of 2,4-thiazolidinedione.
4-hydroxycoumarinNandrolone may increase the anticoagulant activities of 4-hydroxycoumarin.
AcarboseNandrolone may increase the hypoglycemic activities of Acarbose.
AcenocoumarolNandrolone may increase the anticoagulant activities of Acenocoumarol.
AcetohexamideNandrolone may increase the hypoglycemic activities of Acetohexamide.
AICA ribonucleotideNandrolone may increase the hypoglycemic activities of AICA ribonucleotide.
AlbiglutideNandrolone may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe risk or severity of edema formation can be increased when Nandrolone is combined with Aldosterone.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0002725
KEGG Compound
C07254
PubChem Compound
9904
PubChem Substance
347829275
ChemSpider
9520
BindingDB
50080092
RxNav
7244
ChEBI
7466
ChEMBL
CHEMBL757
ZINC
ZINC000003814379
PharmGKB
PA164746281
PDBe Ligand
6VW
Wikipedia
Nandrolone
ATC Codes
S01XA11 — NandroloneA14AB01 — Nandrolone
PDB Entries
5kp4

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentIllness, Critical / Malnutrition1
2, 3CompletedTreatmentMinor burns1
2, 3TerminatedTreatmentMinor burns1
3CompletedTreatmentAplastic Anemia / Blood Diseases / Hematologic Diseases / Pancytopenia1
Not AvailableCompletedSupportive CareCachexia; Cancer1
Not AvailableCompletedTreatmentMuscle Wasting1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0561 mg/mLALOGPS
logP2.6ALOGPS
logP3.07ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)19.28ChemAxon
pKa (Strongest Basic)-0.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.95 m3·mol-1ChemAxon
Polarizability32.19 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-05i3-8950000000-2aca1e24a2ef4acf545f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0090000000-494e848349f5e9b86582
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0570-1980000000-e03a1bc79e9f4e2d8260
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-2900000000-e8dd93d5cf0dff8b90e4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a5c-7900000000-71f3c599cf3161ab0eb7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-057l-9500000000-ab3f2a34ef86ef591844
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0490000000-ef50b9f0fd0a9e2b7c03

Taxonomy

Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-oxo delta-4-steroids / 17-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Secondary alcohols / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Estrogen-skeleton / 3-oxo-delta-4-steroid / 3-oxosteroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Delta-4-steroid / Cyclohexenone / Cyclic alcohol / Cyclic ketone
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo Delta(4)-steroid, 17beta-hydroxy steroid, anabolic androgenic steroid (CHEBI:7466) / Estrane and derivatives (C07254) / C18 steroids (estrogens) and derivatives (LMST02010044)

Drug created on February 15, 2017 12:13 / Updated on March 01, 2020 21:26

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates